Under pressure, Novo lays out blockbuster launch plans
Novo has revealed a plan to launch five or more blockbusters between now and 2030 that it hopes will grow annual revenues by around $23bn.
Telix to buy radiopharma rival ITM for $1.65bn upfront
Telix Pharma has reached a deal to acquire ITM, extending a wave of consolidation in the radiopharma category over the last couple of years.
AZ's gMG drug Klygefa nears EU approval
AstraZeneca's generalised myasthenia gravis (gMG) therapy Klygefa gets CHMP recommendation, alongside several other novel medicines.
Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer
Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
CHMP backs Novo's haemophilia A drug Frehemgo
Novo has moved a step closer to EU approval of its long-acting haemophilia A therapy, Frehemgo, which could be a future blockbuster.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
PMi Awards 2026 – The Winners and Highlights
Avalere Health is the night’s most awarded agency - Novo Nordisk, Roche, and The Urology Foundation top the client leaderboard
RNA-Targeted Small Molecules: From Discovery to Clinic
Leading pharma, biotech and academic experts discuss the future of RNA therapeutics.
Novel CNS Biomarkers Summit Europe
Europe is rapidly becoming a hub for next-generation CNS biomarker innovation
Who's Speaking at the DIA-MHRA Global Summit 2026?
See who's speaking when regulators and industry convene at the DIA-MHRA Global Summit
4th Cell Therapy for Autoimmune Disease Summit
Developers are racing to overcome challenges around safety, scalability, durability of response, and patient access